Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions

PD Zavras, A Shastri, M Goldfinger, AK Verma… - Clinical Cancer …, 2021 - AACR
Purpose: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit
and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies …
被引用次数：16 相关文章

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions.

PD Zavras, A Shastri, M Goldfinger… - … Cancer Research: an …, 2021 - europepmc.org
Purpose Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit
and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies …

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

PD Zavras, A Shastri, M Goldfinger, AK Verma… - 2021 - pubmed.ncbi.nlm.nih.gov
Purpose Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit
and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies …
[PDF] academia.edu

[PDF][PDF] Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

PD Zavras, A Shastri, M Goldfinger, AK Verma… - Clin Cancer …, 2021 - academia.edu
Purpose: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit
and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies …
[HTML] nih.gov

[HTML][HTML] Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

PD Zavras, A Shastri, M Goldfinger… - Clinical Cancer …, 2021 - ncbi.nlm.nih.gov
Purpose: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit
and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies …

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

PD Zavras, A Shastri, M Goldfinger… - Clinical Cancer …, 2021 - einstein.elsevierpure.com
Purpose: Azacitidine and decitabine are hypomethylating agents (HMA), that is, both inhibit
and deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies …
[HTML] nih.gov

[HTML][HTML] Clinical trials assessing hypomethylating agents combined with other therapies: causes for failure and potential solutions

PD Zavras, A Shastri, M Goldfinger… - … cancer research: an …, 2021 - ncbi.nlm.nih.gov
Purpose: Azacitidine and decitabine are hypomethylating agents (HMAs), that is, inhibit and
deplete DNA methyltransferase 1 (DNMT1). HMAs are standard single-agent therapies for …